凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
海普瑞(002399)公告正文

海普瑞:2018年第一季度报告全文

公告日期 2018-04-28
股票简称:海普瑞 股票代码:002399
               深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文




深圳市海普瑞药业集团股份有限公司

       2018 年第一季度报告




          2018 年 04 月




                                                                     1
                                 深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文




                         第一节 重要提示


    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真

实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和

连带的法律责任。

    所有董事均已出席了审议本次季报的董事会会议。

    公司负责人李锂、主管会计工作负责人张斌及会计机构负责人(会计主管人

员)张斌声明:保证季度报告中财务报表的真实、准确、完整。




                                                                                       2
                                                      深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文




                                       第二节 公司基本情况

一、主要会计数据和财务指标

公司是否需追溯调整或重述以前年度会计数据
□ 是 √ 否

                                                       本报告期            上年同期         本报告期比上年同期增减

营业收入(元)                                         798,062,177.39     455,637,144.25                    75.15%

归属于上市公司股东的净利润(元)                         41,988,171.45     -12,081,261.64                  447.55%

归属于上市公司股东的扣除非经常性损益的净利润(元)       36,618,514.59     -11,313,061.39                  423.68%

经营活动产生的现金流量净额(元)                       -48,225,972.78      -63,050,808.58                   23.51%

基本每股收益(元/股)                                          0.0337            -0.0097                   447.42%

稀释每股收益(元/股)                                          0.0337            -0.0097                   447.42%

加权平均净资产收益率                                            0.56%             -0.15%                     0.71%

                                                                                            本报告期末比上年度末增
                                                      本报告期末           上年度末
                                                                                                      减

总资产(元)                                         13,021,211,787.11 13,189,413,531.98                    -1.28%

归属于上市公司股东的净资产(元)                     7,491,876,050.79    7,580,397,982.60                   -1.17%

   注:对于上年同期基数为负数,本期数为正数的科目,上表中“本报告期比上年同期增减”栏目所列比例列示为正。

非经常性损益项目和金额

√ 适用 □ 不适用
                                                                                                           单位:元

                            项目                               年初至报告期期末金额                 说明

非流动资产处置损益(包括已计提资产减值准备的冲销部分)                        19,627.27

计入当期损益的政府补助(与企业业务密切相关,按照国家统一标
                                                                            6,178,894.57
准定额或定量享受的政府补助除外)

除上述各项之外的其他营业外收入和支出                                        1,264,270.05

减:所得税影响额                                                             698,019.68

     少数股东权益影响额(税后)                                             1,395,115.35

合计                                                                        5,369,656.86             --

对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公
开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应
说明原因
□ 适用 √ 不适用

       公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》定义、

                                                                                                                     3
                                                         深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文


列举的非经常性损益项目界定为经常性损益的项目的情形。


二、报告期末股东总数及前十名股东持股情况表

1、普通股股东总数和表决权恢复的优先股股东数量及前 10 名股东持股情况表

                                                                                                                单位:股

                                                   报告期末表决权恢复的优先股股
报告期末普通股股东总数                  22,412                                                                         0
                                                   东总数(如有)

                                              前 10 名股东持股情况

                                                                                           持有有限     质押或冻结情况
                股东名称                       股东性质        持股比例      持股数量      售条件的 股份
                                                                                                                数量
                                                                                           股份数量 状态

深圳市乐仁科技有限公司                      境内非国有法人          38.01%   474,029,899            0

乌鲁木齐金田土股权投资合伙企业(有限合伙)境内非国有法人            32.72%   408,041,280            0

乌鲁木齐水滴石穿股权投资合伙企业(有限合
                                            境内非国有法人          3.72%     46,425,600            0
伙)

乌鲁木齐飞来石股权投资有限公司              境内非国有法人          3.23%     40,320,000            0 质押    32,980,000

深圳市海普瑞药业股份有限公司-第二期员工
                                            其他                    1.65%     20,618,035            0
持股计划

云南国际信托有限公司-云南信托聚鑫弘扬 5
                                            其他                    1.09%     13,584,607            0
号集合资金信托计划

湖南省信托有限责任公司-南金 5 号集合资金
                                            其他                    0.99%     12,350,582            0
信托计划

黄镇                                        境内自然人              0.64%      8,000,000            0

长安国际信托股份有限公司-长安信托-长安
                                            其他                    0.63%      7,885,320            0
投资 591 号证券投资集合资金信托计划

湖南省信托有限责任公司-南金 1 号集合资金
                                            其他                    0.57%      7,112,967            0
信托计划

                                       前 10 名无限售条件股东持股情况

                                                                                                 股份种类
                     股东名称                            持有无限售条件股份数量
                                                                                        股份种类             数量

深圳市乐仁科技有限公司                                                  474,029,899 人民币普通股             474,029,899

乌鲁木齐金田土股权投资合伙企业(有限合伙)                              408,041,280 人民币普通股             408,041,280

乌鲁木齐水滴石穿股权投资合伙企业(有限合伙)                              46,425,600 人民币普通股             46,425,600

乌鲁木齐飞来石股权投资有限公司                                            40,320,000 人民币普通股             40,320,000

深圳市海普瑞药业股份有限公司-第二期员工持股计划                          20,618,035 人民币普通股             20,618,035



                                                                                                                           4
                                                       深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文


云南国际信托有限公司-云南信托聚鑫弘扬 5 号集合资
                                                                      13,584,607 人民币普通股       13,584,607
金信托计划

湖南省信托有限责任公司-南金 5 号集合资金信托计划                     12,350,582 人民币普通股       12,350,582

黄镇                                                                   8,000,000 人民币普通股        8,000,000

长安国际信托股份有限公司-长安信托-长安投资 591 号
                                                                       7,885,320 人民币普通股        7,885,320
证券投资集合资金信托计划

湖南省信托有限责任公司-南金 1 号集合资金信托计划                      7,112,967 人民币普通股        7,112,967

                                                      深圳市乐仁科技有限公司和乌鲁木齐金田土股权投资合伙企业
                                                      (有限合伙)的股东(合伙人)为李锂和李坦,乌鲁木齐飞来石
                                                      股权投资有限公司的股东为李锂,乌鲁木齐水滴石穿股权投资合
                                                      伙企业(有限合伙)的合伙人为单宇和李坦,李锂和李坦为夫妻
上述股东关联关系或一致行动的说明                      关系,单宇和李坦为兄妹关系,单宇参与公司第二期员工持股计
                                                      划,参加份额为 38.88%。除上述情况外,公司未知其他前十名
                                                      股东之间是否存在关联关系,也未知是否属于一致行动人;公司
                                                      未知其他前十名无限售条件股东之间是否存在关联关系,也未知
                                                      是否属于一致行动人。

前 10 名普通股股东参与融资融券业务情况说明(如有) 无

公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内是否进行约定购回交易
□ 是 √ 否

       公司前10名普通股股东、前10名无限售条件普通股股东在报告期内未进行约定购回交易。


2、公司优先股股东总数及前 10 名优先股股东持股情况表

□ 适用 √ 不适用




                                                                                                                 5
                                                            深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文




                                              第三节 重要事项

一、报告期主要财务数据、财务指标发生变动的情况及原因

√ 适用 □ 不适用

资产负债表项目变动原因

       项目           本报告期末       本报告期初       同比增减                           变动原因

长期应收款             3,530,536.62     2,529,274.60       39.59% 报告期内美国子公司 SPL 应收利息增加所致

                                                                    报告期内子公司成都海通因应付的银行承兑汇票到期承兑导
应付票据                       0.00     3,343,678.44     -100.00%
                                                                    致应付票据减少

                                                                    报告期内母公司支付上年计提的双薪,绩效奖金以及加班工资
应付职工薪酬          47,666,456.48    81,165,534.33      -41.27%
                                                                    所致

                                                                    报告期内母公司支付 2017 年第四季度的所得税费用以及子公
应交税费               9,520,413.45    18,428,984.48      -48.34%
                                                                    司山东瑞盛支付 2017 年的应交增值税所致

应付利息              24,068,383.50    15,277,152.40       57.54% 报告期内计提的债券利息和银行贷款利息增加所致

长期借款            1,092,407,226.11 826,576,300.00        32.16% 报告期内子公司 Hepalink USA Inc.长期借款增加所致

利润表项目变动原因

       项目            本报告期         上年同期        同比增减                           变动原因

                                                                    报告期内母公司肝素钠原料药销售均价和销售量增加以及子
营业收入             798,062,177.39 455,637,144.25         75.15%
                                                                    公司 SPL 胰酶原料药的销售均价和销售量增加所致

                                                                    报告期内母公司肝素钠原料药单位成本和销售量增加以及子
营业成本             546,246,355.49 344,526,952.77         58.55%
                                                                    公司胰酶原料药的销售量增加所致

销售费用              21,862,598.53     7,836,170.90      179.00% 报告期内子公司成都海通广告费、中介机构费增加所致

                                                                    报告期内母公司与境外子公司美国海普瑞内部往来款因人民
财务费用              70,659,801.89    12,330,288.65      473.06%
                                                                    币对美元升值导致汇兑损失增加所致

资产减值损失              47,666.90       282,491.71      -83.13% 报告期内子公司 SPL 计提的存货跌价准备转回所致

                                                                    上年同期货币交叉掉期合约平仓结算结转公允价值,而报告期
公允价值变动收益               0.00     -6,535,944.23     100.00%
                                                                    内不存在相关交易所致

                                                                    报告期内母公司银行理财产品投资收益增加以及母公司以权
投资收益               -9,499,125.75      493,581.11    -2024.53% 益法核算的长期股权投资确认的投资损失增加的共同影响所
                                                                    致

资产处置收益              20,000.00             0.00                报告期内子公司朋和物业处置固定资产取得的收益

                                                                    报告期内母公司和子公司深圳君圣泰生物技术有限公司收到
其他收益               6,178,894.57     3,204,056.11       92.85%
                                                                    的政府补助增加所致

营业利润              48,533,396.34    -21,483,395.15     325.91% 报告期内销售毛利增加所致


                                                                                                                      6
                                                             深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文


营业外收入               1,273,348.41       49,642.22     2465.05% 报告期内子公司 Hepalink USA Inc.营业外收入增加所致

营业外支出                   9,451.09        17,690.7      -46.58% 报告期内子公司成都海通支付安全保证金减少所致

利润总额                49,797,293.66   -21,451,443.63     332.14% 报告期内营业利润增加所致

所得税费用              17,867,473.52    -6,904,167.24     358.79% 报告期内税前利润增加所致

少数股东损益           -10,058,351.31    -2,466,014.75    -307.88% 报告期内控股子公司亏损增加所致

归属于母公司股东
                        41,988,171.45   -12,081,261.64     447.55% 报告期内利润总额增加所致
的净利润

归属母公司股东的
                                                                     报告期内归属母公司股东的外币报表折算差额减少及可供出
其他综合收益的税 -130,510,103.26        39,569,799.51     -429.82%
                                                                     售金融资产公允价值变动损失增加所致
后净额

归属于少数股东的
其他综合收益的税          -404,204.51      302,161.57     -233.77% 报告期内归属于少数股东的外币报表折算差额减少所致
后净额

现金流量表项目变动原因

         项目           本报告期         上年同期        同比增减                           主要变动原因

                                                                     报告期内,销售商品收到的现金同比增加以及购买原材料支付
经营活动产生的现
                       -48,225,972.78   -63,050,808.58      23.51% 的现金同比增加、支付其他与经营活动有关的现金同比增加的
金流量净额
                                                                     综合影响所致

投资活动产生的现                                                     报告期内赎回理财产品收到的现金减少以及投资金融资产支
                       -39,000,310.26 -339,025,043.35       88.50%
金流量净额                                                           付的现金同比增加所致

筹资活动产生的现                                                     报告期内母公司及子公司美国海普瑞向银行借款收到的现金
                        99,792,641.74   -31,304,398.16     418.78%
金流量净额                                                           同比减少,较偿还银行借款支付的现金同比减少的幅度小所致

汇率变动对现金的                                                     报告期内人民币升值的幅度大于去年同期导致汇兑损失增加
                       -10,491,712.00    -2,150,661.47    -387.84%
影响

现金及现金等价物                                                     报告期内经营活动和投资活动产生的现金流出净额减少、筹资
                         2,074,646.70 -435,530,911.56      100.48%
净增加额                                                             活动产生的现金流入净额增加共同所致


二、重要事项进展情况及其影响和解决方案的分析说明

√ 适用 □ 不适用

       1 、 2014 年 11 月 3 日 , 公 司 第 三 届 董 事 会 第 五 次 会 议 审 议 通 过 《 关 于 公 司 使 用 自 有 资 金 对 TPG

BIOTECHNOLOGY PARTNERS IV, L.P.进行投资的议案》,同意公司使用17,358,389美元自有资金对TPG

Biotechnology Partners IV, L.P.进行投资(对应份额16,150,000美元),同时以500万美元自有资金购买有限

合伙人TPG Holdings I, L.P.和TPG Holdings II, L.P.认缴TPG的500万美元份额,共计投资22,358,389美元。报

告期内,公司按照投资付款通知,实际支付726,802.00美元,截至本公告日,已累计支付21,196,981.00 美

元。


                                                                                                                          7
                                                     深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文


    2、2015年3月18日,公司第三届董事会第八次会议审议通过了《关于设立产业并购基金的议案》,决

定设立深圳市德康投资发展有限公司,注册资本1,000万元。德康投资与北京鑫羊投资管理有限责任公司、

北京格兰德丰投资管理中心(有限合伙)等共同成立北京枫海资本管理中心(有限合伙),枫海资本认缴

出资总额250万元。待枫海资本成立后,再由该枫海资本作为普通合伙人,海普瑞作为有限合伙人共同成

立“深圳枫海资本并购基金(有限合伙)”。报告期内,公司按照投资付款通知,实际支付495万元人民币,

截至本公告日,已累计支付20,352.35万元人民币。

    3、2015年8月27日,公司第三届董事会第十五次会议审议通过了《关于设立新药基金的议案》,详细

内容参见2015年8月29日刊登于《证券时报》、《中国证券报》、《上海证券报》、《证券日报》和巨潮

资讯网 www.cninfo.com.cn 的《关于设立新药基金的公告》。报告期内,公司未收到投资付款通知。截至

本公告日,已累计支付8,925万人民币。

    4、2016年6月16日,公司第三届董事会第二十二次会议审议通过《关于公司使用自有资金对TPG

BIOTECHNOLOGY PARTNERS V, L.P.投资的议案》,同意使用6,000万美元自有资金参与投资TPG

Biotechnology Partners V, L.P.。详细容参见2016年6月17日刊登于《证券时报》、《中国证券报》、《上海

证 券 报 》 、 《 证 券 日 报 》 和 巨 潮 资 讯 网 www.cninfo.com.cn 的 《 关 于 公 司 使 用 自 有 资 金 对 TPG

BIOTECHNOLOGY PARTNERS V, L.P.投资的公告》。报告期内,公司未收到投资付款通知,截至本公告

日,已累计支付20,596,010.00 美元。

    5、2016年9月20日,第三届董事会第二十六次会议审议通过了《关于对全资子公司海普瑞(香港)有

限公司进行增资的议案》,同意公司以自有资金5,500万美元(或等值人民币)增加对香港海普瑞的投资,

详细内容参见2016年9月21日刊登于《证券时报》、《中国证券报》、《上海证券报》、《证券日报》和

巨潮资讯网 www.cninfo.com.cn 的《关于对全资子公司海普瑞(香港)有限公司进行增资的公告》。截至

本公告日,该项增资尚未完成。

    6、2016年11月18日,第三届董事会第二十八会议审议通过了《关于对全资子公司Hepalink USA Inc.

增资的议案》,同意公司以自有资金折合人民币5亿元增加对美国海普瑞的投资,详细内容参见2016年11

月19日刊登于《证券时报》、《中国证券报》、《上海证券报》、《证券日报》和巨潮资讯网 www.cninfo.com.cn

的《关于对全资子公司Hepalink USA Inc.增资的公告》。截至本公告日,该项增资尚未完成。

    7、2018年2月11日,公司第四届董事会第十一次会议审议通过了《关于审议公司购买资产暨关联交易

方案的议案》,经2018年第二次临时股东大会审议通过,本次收购多普乐方案改为现金方式收购,多普乐

已于2018年4月完成工商登记变更并取得新的营业执照,详细内容参见2018年4月4日刊登于《证券时报》、

《中国证券报》、《上海证券报》、《证券日报》和巨潮资讯网 www.cninfo.com.cn 的《关于购买资产

暨关联交易的进展公告》。

                                                                                                             8
                                                            深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文


     8、2018年2月11日,第四届董事会第十一次会议审议通过《关于公司与Aridis设立合资子公司的议案》,

同意公司认缴出资600万美元现金或等值货币,与Aridis在中国共同投资设立合资公司。详细内容参见2018

年2月12日刊登于《证券时报》、 中国证券报》、 上海证券报》、 证券日报》和巨潮资讯网 www.cninfo.com.cn

的《关于公司与Aridis设立合资子公司的公告》。

             重要事项概述                       披露日期                      临时报告披露网站查询索引

                                          2018 年 01 月 07 日 http://disclosure.szse.cn/finalpage/2018-01-06/1204309442.PDF
关于公司和全资孙公司共同对外投资事
                                          2018 年 01 月 17 日 http://disclosure.szse.cn/finalpage/2018-01-17/1204335983.PDF

                                          2018 年 03 月 03 日 http://disclosure.szse.cn/finalpage/2018-03-03/1204446291.PDF

关于公司与 Aridis 设立合资子公司事项 2018 年 02 月 12 日 http://disclosure.szse.cn/finalpage/2018-02-12/1204415431.PDF

                                          2018 年 02 月 12 日 http://disclosure.szse.cn/finalpage/2018-02-12/1204415431.PDF

关于购买资产暨关联交易事项                2018 年 03 月 06 日 http://disclosure.szse.cn/finalpage/2018-03-06/1204452712.PDF

                                          2018 年 04 月 04 日 http://disclosure.szse.cn/finalpage/2018-04-04/1204585053.PDF


三、公司实际控制人、股东、关联方、收购人以及公司等承诺相关方在报告期内超期未履行
完毕的承诺事项

√ 适用 □ 不适用

      承诺事由           承诺方       承诺类型                  承诺内容                  承诺时间     承诺期限 履行情况

股改承诺              不适用

收购报告书或权益变
                      不适用
动报告书中所作承诺

资产重组时所作承诺    不适用

                      深圳市乐仁
                                                 1、在本公司作为公司控股股东期间/在
                      科技有限公
                                                 本人作为公司实际控制人期间/在本人
                      司;乌鲁木
                                                 作为公司董事、总经理期间,本公司/
                      齐飞来石股
                                     关于同业竞 本人保证不自营或以合资、合作等方式                                报告期
                      权投资有限
                                     争、关联交 经营任何与公司现从事的业务有竞争的                                内,承诺
                      公司;乌鲁                                                          2010 年 04
                                     易、资金占 业务,本公司现有的或将来成立的全资                                人严格履
                      木齐金田土                                                          月 23 日
                                     用方面的承 子公司、控股子公司以及其他受本公司                                行了上述
首次公开发行或再融    股权投资合
                                     诺          控制的企业亦不会经营与公司现从事的                               承诺
资时所作承诺          伙企业(有
                                                 业务有竞争的业务。2、如违反上述承诺,
                      限合伙);李
                                                 本公司同意承担给公司造成的全部损
                      锂;李坦;
                                                 失。
                      单宇

                      深圳市乐仁                 1、如今后公司或子公司深圳市多普生生                              报告期
                      科技有限公                 物技术有限公司因依据深府[1988]232 2010 年 04                   内,承诺
                                     其他承诺
                      司;乌鲁木                 号文享受的企业所得税优惠被税务机关 月 23 日                      人严格履
                      齐金田土股                 撤消而产生的额外税项和费用时,将及                               行了上述



                                                                                                                              9
                                                      深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文


                       权投资合伙            时、无条件、全额返还公司或深圳市多                     承诺
                       企业(有限            普生生物技术有限公司补缴的税款以及
                       合伙)                因此所产生的所有相关费用。2、如今后
                                             公司因以实际缴纳的增值税和营业税税
                                             额为计税依据缴纳城市维护建设税和教
                                             育费附加事宜被税务机关追缴而产生额
                                             外税项和费用时,将及时、无条件、全
                                             额返还公司补缴的税款以及因此所产生
                                             的所有相关费用。

                       深圳市乐仁            如今后公司或子公司深圳市多普生生物
                       科技有限公            技术有限公司因上市前执行住房公积金                     报告期
                       司;乌鲁木            政策事宜被要求补缴住房公积金、缴纳                     内,承诺
                                                                                   2010 年 04
                       齐金田土股 其他承诺   罚款或因此遭受任何损失时,将及时、                     人严格履
                                                                                   月 23 日
                       权投资合伙            无条件、全额返还公司或深圳市多普生                     行了上述
                       企业(有限            生物技术有限公司由此遭受的一切损                       承诺
                       合伙)                失。

                                             1、在深圳市天道医药有限公司与深圳市
                                                                                                    报告期
                                             多普乐实业发展有限公司生产的低分子
                                                                                                    内,承诺
                                             肝素制剂获得美国 FDA 或欧盟 EDQM
                                                                                                    人严格履
                                             的药政注册,并被批准上市实现正式的
                                                                                                    行了上述
                                             商业销售,同时一个会计年度内累计关
                                                                                                    承诺,启
                                             联交易金额达到公司当期经审计的营业
                                                                                   2010 年 04       动注入程
                       李锂;李坦 其他承诺   收入的百分之五后,承诺人同意在取得
                                                                                   月 23 日         序,已于
                                             公司董事会和股东大会批准并履行相关
                                                                                                    2018 年 4
                                             的政府审批程序后,将所持深圳市天道
                                                                                                    月完成多
                                             医药有限公司与深圳市多普乐实业发展
                                                                                                    普乐工商
                                             有限公司的全部股权按市场公允价值作
                                                                                                    变更登
                                             价注入公司。2、如违反上述承诺,承诺
                                                                                                    记。
                                             人同意承担给公司造成的全部损失。

股权激励承诺           不适用

其他对公司中小股东
                       不适用
所作承诺

承诺是否按时履行       是

如承诺超期未履行完
毕的,应当详细说明未
                       无
完成履行的具体原因
及下一步的工作计划


四、对 2018 年 1-6 月经营业绩的预计

2018 年 1-6 月预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形
归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形



                                                                                                             10
                                                            深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文


2018 年 1-6 月归属于上市公司股东的净利润变动幅度                       1,376.49%      至                      1,779.17%

2018 年 1-6 月归属于上市公司股东的净利润变动区间(万元)                   11,000     至                             14,000

2017 年 1-6 月归属于上市公司股东的净利润(万元)                                                                     745.01

                                                              主要原因包括:1、海普瑞和 SPL 肝素钠原料药销售量上升
                                                              和销售价格上涨带来毛利增加;2、SPL 胰酶原料药销售增长;
业绩变动的原因说明
                                                              3、利息费用、内部往来款的汇兑损失和按照权益法合并
                                                              Resverlogix Corp.的投资导致投资损失增加

   注:由于去年同期业绩基数较小,导致根据深交所规则预计变动幅度在 50%以内无法准确预计业绩区间,故根据公司实
际情况预计变动幅度在 1,376.49%至 1,779.17%之间。


五、以公允价值计量的金融资产

√ 适用 □ 不适用
                                                                                                                单位:元

                               本期公允价值变 计入权益的累计        报告期内购    报告期内 累计投                     资金
 资产类别    初始投资成本                                                                            期末金额
                                   动损益         公允价值变动        入金额      售出金额 资收益                     来源

                                                                                                                     自有
   股票        93,791,214.57    -102,934,146.33    132,424,806.93                                   226,216,021.50
                                                                                                                     资金

                                                                                                                     自有
   基金      290,284,976.25        -500,725.95     -22,301,572.71 15,233,520.17                     267,983,403.55
                                                                                                                     资金

   合计      384,076,190.82     -103,434,872.28    110,123,234.22 15,233,520.17       0.00    0.00 494,199,425.05      --


六、违规对外担保情况

□ 适用 √ 不适用

     公司报告期无违规对外担保情况。


七、控股股东及其关联方对上市公司的非经营性占用资金情况

□ 适用 √ 不适用

     公司报告期不存在控股股东及其关联方对上市公司的非经营性占用资金。


八、报告期内接待调研、沟通、采访等活动登记表

□ 适用 √ 不适用

     公司报告期内未发生接待调研、沟通、采访等活动。




                                                                                                                            11
                                                    深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文




                                        第四节 财务报表

一、财务报表

1、合并资产负债表

编制单位:深圳市海普瑞药业集团股份有限公司
                                             2018 年 03 月 31 日
                                                                                                       单位:元

                 项目                          期末余额                             期初余额

流动资产:

    货币资金                                              3,495,473,266.66                     3,495,559,006.61

    结算备付金

    拆出资金

    以公允价值计量且其变动计入当
期损益的金融资产

    衍生金融资产

    应收票据                                               134,710,397.93                       131,096,447.98

    应收账款                                               798,640,332.79                       760,239,700.86

    预付款项                                               272,667,997.02                       255,175,986.33

    应收保费

    应收分保账款

    应收分保合同准备金

    应收利息                                               214,288,623.53                       202,848,820.85

    应收股利

    其他应收款                                              94,847,317.59                        96,470,898.52

    买入返售金融资产

    存货                                                   920,156,694.73                       857,271,426.77

    持有待售的资产

    一年内到期的非流动资产

    其他流动资产                                           247,276,641.34                       331,064,404.71

流动资产合计                                              6,178,061,271.59                     6,129,726,692.63

非流动资产:

    发放贷款及垫款



                                                                                                             12
                                   深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文


    可供出售金融资产                  1,363,337,293.35                     1,461,532,170.16

    持有至到期投资

    长期应收款                            3,530,536.62                         2,529,274.60

    长期股权投资                       603,777,159.41                        621,440,389.73

    投资性房地产

    固定资产                           809,098,693.66                        839,487,291.35

    在建工程                           805,540,465.15                        769,797,937.14

    工程物资

    固定资产清理

    生产性生物资产

    油气资产

    无形资产                           596,596,722.58                        625,057,629.92

    开发支出                            12,974,194.14                         12,644,460.61

    商誉                              2,122,630,617.96                     2,205,704,900.35

    长期待摊费用                       213,803,957.45                        216,027,877.64

    递延所得税资产                     121,602,931.81                        140,731,439.86

    其他非流动资产                     190,257,943.39                        164,733,467.99

非流动资产合计                        6,843,150,515.52                     7,059,686,839.35

资产总计                             13,021,211,787.11                    13,189,413,531.98

流动负债:

    短期借款                          1,340,262,886.54                     1,361,047,500.00

    向中央银行借款

    吸收存款及同业存放

    拆入资金

    以公允价值计量且其变动计入当
期损益的金融负债

    衍生金融负债

    应付票据                                                                   3,343,678.44

    应付账款                           118,228,847.65                        139,347,982.25

    预收款项                            54,035,081.25                         50,833,608.46

    卖出回购金融资产款

    应付手续费及佣金

    应付职工薪酬                        47,666,456.48                         81,165,534.33

    应交税费                              9,520,413.45                        18,428,984.48




                                                                                         13
                             深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文


    应付利息                      24,068,383.50                         15,277,152.40

    应付股利

    其他应付款                    39,395,589.48                         54,745,266.06

    应付分保账款

    保险合同准备金

    代理买卖证券款

    代理承销证券款

    持有待售的负债

    一年内到期的非流动负债      1,313,952,148.21                     1,524,951,151.67

    其他流动负债                    1,498,981.30                         1,626,772.47

流动负债合计                    2,948,628,787.86                     3,250,767,630.56

非流动负债:

    长期借款                    1,092,407,226.11                       826,576,300.00

    应付债券                     993,236,367.79                        992,786,797.79

      其中:优先股

            永续债

    长期应付款                      8,665,051.04                         9,832,671.09

    长期应付职工薪酬              65,832,481.97                         67,914,998.07

    专项应付款                       113,592.16                           103,244.32

    预计负债                        8,650,159.49                         8,988,704.41

    递延收益                      26,205,014.69                         29,674,909.26

    递延所得税负债               289,859,370.12                        316,170,052.97

    其他非流动负债

非流动负债合计                  2,484,969,263.37                     2,252,047,677.91

负债合计                        5,433,598,051.23                     5,502,815,308.47

所有者权益:

    股本                        1,247,201,704.00                     1,247,201,704.00

    其他权益工具

      其中:优先股

            永续债

    资本公积                    4,216,571,968.87                     4,216,571,968.87

    减:库存股

    其他综合收益                  98,713,968.47                        229,224,071.73

    专项储备



                                                                                   14
                                                深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文


    盈余公积                                           490,284,765.67                       490,284,765.67

    一般风险准备

    未分配利润                                        1,439,103,643.78                     1,397,115,472.33

归属于母公司所有者权益合计                            7,491,876,050.79                     7,580,397,982.60

    少数股东权益                                        95,737,685.09                       106,200,240.91

所有者权益合计                                        7,587,613,735.88                     7,686,598,223.51

负债和所有者权益总计                              13,021,211,787.11                    13,189,413,531.98


法定代表人:李锂                   主管会计工作负责人:张斌                       会计机构负责人:张斌


2、母公司资产负债表

                                                                                                   单位:元

                 项目                      期末余额                             期初余额

流动资产:

    货币资金                                          3,116,823,492.81                     3,227,938,630.55

    以公允价值计量且其变动计入当
期损益的金融资产

    衍生金融资产

    应收票据                                           138,200,685.54                       133,563,701.92

    应收账款                                           499,102,535.89                       493,219,282.11

    预付款项                                           510,742,572.29                       483,539,793.06

    应收利息                                           343,843,144.79                       333,499,989.53

    应收股利

    其他应收款                                         380,708,724.72                       446,147,566.60

    存货                                               470,767,924.12                       429,866,372.13

    持有待售的资产

    一年内到期的非流动资产

    其他流动资产                                       182,289,863.32                       272,058,420.27

流动资产合计                                          5,642,478,943.48                     5,819,833,756.17

非流动资产:

    可供出售金融资产                                   575,840,786.90                       608,207,193.47

    持有至到期投资

    长期应收款                                         778,777,010.00                       808,825,820.00

    长期股权投资                                      2,367,407,067.86                     2,375,604,730.39

    投资性房地产


                                                                                                         15
                                   深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文


    固定资产                           173,053,016.01                        177,172,471.88

    在建工程                           471,176,744.81                        435,048,205.40

    工程物资

    固定资产清理

    生产性生物资产

    油气资产

    无形资产                           102,323,554.55                        103,591,834.85

    开发支出                                94,387.55                             76,098.55

    商誉

    长期待摊费用                        90,355,980.29                         91,904,723.27

    递延所得税资产                      12,312,105.77                         10,339,956.39

    其他非流动资产                      62,236,934.37                         37,796,177.17

非流动资产合计                        4,633,577,588.11                     4,648,567,211.37

资产总计                             10,276,056,531.59                    10,468,400,967.54

流动负债:

    短期借款                          1,290,262,886.54                     1,361,047,500.00

    以公允价值计量且其变动计入当
期损益的金融负债

    衍生金融负债

    应付票据

    应付账款                            18,569,250.43                         30,431,059.43

    预收款项

    应付职工薪酬                        19,315,743.44                         39,860,373.80

    应交税费                              5,024,304.95                        11,720,048.91

    应付利息                            15,470,031.85                          7,080,232.49

    应付股利

    其他应付款                         158,502,401.87                        145,816,726.26

    持有待售的负债

    一年内到期的非流动负债

    其他流动负债

流动负债合计                          1,507,144,619.08                     1,595,955,940.89

非流动负债:

    长期借款

    应付债券                           993,236,367.79                        992,786,797.79




                                                                                         16
                                   深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文


      其中:优先股

             永续债

    长期应付款

    长期应付职工薪酬

    专项应付款

    预计负债

    递延收益                               10,081,300.15                        10,253,643.13

    递延所得税负债                         15,114,085.15                        30,524,140.29

    其他非流动负债

非流动负债合计                        1,018,431,753.09                     1,033,564,581.21

负债合计                              2,525,576,372.17                     2,629,520,522.10

所有者权益:

    股本                              1,247,201,704.00                     1,247,201,704.00

    其他权益工具

      其中:优先股

             永续债

    资本公积                          4,248,203,399.82                     4,248,203,399.82

    减:库存股

    其他综合收益                       129,583,216.62                          216,906,862.41

    专项储备

    盈余公积                           490,284,765.67                          490,284,765.67

    未分配利润                        1,635,207,073.31                     1,636,283,713.54

所有者权益合计                        7,750,480,159.42                     7,838,880,445.44

负债和所有者权益总计                 10,276,056,531.59                    10,468,400,967.54


3、合并利润表

                                                                                     单位:元

                 项目         本期发生额                          上期发生额

一、营业总收入                             798,062,177.39                      455,637,144.25

    其中:营业收入                         798,062,177.39                      455,637,144.25

           利息收入

           已赚保费

           手续费及佣金收入

二、营业总成本                             746,228,549.87                      474,282,232.39



                                                                                           17
                                         深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文


    其中:营业成本                            546,246,355.49                       344,526,952.77

           利息支出

           手续费及佣金支出

           退保金

           赔付支出净额

           提取保险合同准备金净额

           保单红利支出

           分保费用

           税金及附加                           3,507,960.06                         2,960,391.78

           销售费用                            21,862,598.53                         7,836,170.90

           管理费用                           103,904,167.00                       106,345,936.58

           财务费用                            70,659,801.89                        12,330,288.65

           资产减值损失                            47,666.90                          282,491.71

    加:公允价值变动收益(损失以
                                                                                    -6,535,944.23
“-”号填列)

         投资收益(损失以“-”号填
                                               -9,499,125.75                           493,581.11
列)

         其中:对联营企业和合营企业
                                              -15,555,043.85                        -2,859,737.19
的投资收益

         汇兑收益(损失以“-”号填列)

         资产处置收益(损失以“-”号填
                                                   20,000.00
列)

         其他收益                               6,178,894.57                         3,204,056.11

三、营业利润(亏损以“-”号填列)             48,533,396.34                       -21,483,395.15

    加:营业外收入                              1,273,348.41                            49,642.22

    减:营业外支出                                  9,451.09                            17,690.70

四、利润总额(亏损总额以“-”号填列)         49,797,293.66                       -21,451,443.63

    减:所得税费用                             17,867,473.52                        -6,904,167.24

五、净利润(净亏损以“-”号填列)             31,929,820.14                       -14,547,276.39

    (一)持续经营净利润(净亏损以
                                               31,929,820.14                       -14,547,276.39
“-”号填列)

    (二)终止经营净利润(净亏损以
“-”号填列)

    归属于母公司所有者的净利润                 41,988,171.45                       -12,081,261.64

    少数股东损益                              -10,058,351.31                        -2,466,014.75

六、其他综合收益的税后净额                   -130,914,307.77                        39,871,961.08


                                                                                               18
                                                    深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文


  归属母公司所有者的其他综合收益
                                                           -130,510,103.26                      39,569,799.51
的税后净额

    (一)以后不能重分类进损益的其
他综合收益

           1.重新计量设定受益计划净
负债或净资产的变动

           2.权益法下在被投资单位不
能重分类进损益的其他综合收益中享
有的份额

    (二)以后将重分类进损益的其他
                                                           -130,510,103.26                      39,569,799.51
综合收益

           1.权益法下在被投资单位以
后将重分类进损益的其他综合收益中
享有的份额

           2.可供出售金融资产公允价
                                                            -84,101,279.95                      42,992,766.10
值变动损益

           3.持有至到期投资重分类为
可供出售金融资产损益

           4.现金流量套期损益的有效
部分

           5.外币财务报表折算差额                           -46,408,823.31                      -3,422,966.59

           6.其他

  归属于少数股东的其他综合收益的
                                                              -404,204.51                         302,161.57
税后净额

七、综合收益总额                                            -98,984,487.63                      25,324,684.69

    归属于母公司所有者的综合收益
                                                            -88,521,931.81                      27,488,537.87
总额

    归属于少数股东的综合收益总额                            -10,462,555.82                      -2,163,853.18

八、每股收益:

    (一)基本每股收益                                             0.0337                             -0.0097

    (二)稀释每股收益                                             0.0337                             -0.0097

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:元,上期被合并方实现的净利润为:元。


法定代表人:李锂                       主管会计工作负责人:张斌                       会计机构负责人:张斌


4、母公司利润表

                                                                                                     单位:元

                 项目                         本期发生额                           上期发生额


                                                                                                           19
                                       深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文


一、营业收入                               362,675,657.49                        170,055,941.88

    减:营业成本                           269,927,639.87                        120,841,306.86

         税金及附加                          1,374,692.65                          2,280,627.36

         销售费用                            1,483,524.18                           888,493.37

         管理费用                           33,092,359.29                         37,823,341.93

         财务费用                           53,630,494.09                        -16,603,174.13

         资产减值损失                                                               -227,002.43

    加:公允价值变动收益(损失以
                                                                                  -6,535,944.23
“-”号填列)

         投资收益(损失以“-”号填
                                             -7,318,533.23                         2,968,762.09
列)

         其中:对联营企业和合营企
                                            -13,147,662.53
业的投资收益

         资产处置收益(损失以“-”号
填列)

         其他收益                            2,881,342.98                           159,843.00

二、营业利润(亏损以“-”号填列)           -1,270,242.84                        21,645,009.78

    加:营业外收入                               3,980.00                              4,000.00

    减:营业外支出                                 372.73                              4,042.15

三、利润总额(亏损总额以“-”号填
                                             -1,266,635.57                        21,644,967.63
列)

    减:所得税费用                            -189,995.34                          2,300,403.87

四、净利润(净亏损以“-”号填列)           -1,076,640.23                        19,344,563.76

    (一)持续经营净利润(净亏损
                                             -1,076,640.23                        19,344,563.76
以“-”号填列)

    (二)终止经营净利润(净亏损
以“-”号填列)

五、其他综合收益的税后净额                  -87,323,645.79                        42,008,969.04

    (一)以后不能重分类进损益的
其他综合收益

           1.重新计量设定受益计划
净负债或净资产的变动

           2.权益法下在被投资单位
不能重分类进损益的其他综合收益中
享有的份额

    (二)以后将重分类进损益的其
                                            -87,323,645.79                        42,008,969.04
他综合收益


                                                                                             20
                                          深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文


           1.权益法下在被投资单位
以后将重分类进损益的其他综合收益
中享有的份额

           2.可供出售金融资产公允
                                                  -87,323,645.79                      42,008,969.04
价值变动损益

           3.持有至到期投资重分类
为可供出售金融资产损益

           4.现金流量套期损益的有
效部分

           5.外币财务报表折算差额

           6.其他

六、综合收益总额                                  -88,400,286.02                      61,353,532.80

七、每股收益:

     (一)基本每股收益

     (二)稀释每股收益


5、合并现金流量表

                                                                                           单位:元

               项目                 本期发生额                          上期发生额

一、经营活动产生的现金流量:

     销售商品、提供劳务收到的现金                766,189,003.39                      440,065,557.40

     客户存款和同业存放款项净增
加额

     向中央银行借款净增加额

     向其他金融机构拆入资金净增
加额

     收到原保险合同保费取得的现


     收到再保险业务现金净额

     保户储金及投资款净增加额

     处置以公允价值计量且其变动
计入当期损益的金融资产净增加额

     收取利息、手续费及佣金的现金

     拆入资金净增加额

     回购业务资金净增加额

     收到的税费返还                               26,457,401.65                        5,251,806.82



                                                                                                 21
                                    深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文


     收到其他与经营活动有关的现
                                        15,514,978.25                          24,127,755.14


经营活动现金流入小计                   808,161,383.29                         469,445,119.36

     购买商品、接受劳务支付的现金      613,817,414.27                         299,928,902.46

     客户贷款及垫款净增加额

     存放中央银行和同业款项净增
加额

     支付原保险合同赔付款项的现


     支付利息、手续费及佣金的现金

     支付保单红利的现金

     支付给职工以及为职工支付的
                                       153,899,131.62                         153,015,831.65
现金

     支付的各项税费                     21,902,252.17                          42,766,386.13

     支付其他与经营活动有关的现
                                        66,768,558.01                          36,784,807.70


经营活动现金流出小计                   856,387,356.07                         532,495,927.94

经营活动产生的现金流量净额              -48,225,972.78                        -63,050,808.58

二、投资活动产生的现金流量:

     收回投资收到的现金                254,945,968.32                         467,680,000.00

     取得投资收益收到的现金              3,957,708.49                           3,617,726.40

     处置固定资产、无形资产和其他
                                            20,000.00                                830.00
长期资产收回的现金净额

     处置子公司及其他营业单位收
到的现金净额

     收到其他与投资活动有关的现


投资活动现金流入小计                   258,923,676.81                         471,298,556.40

     购建固定资产、无形资产和其他
                                       105,921,096.90                         139,133,784.70
长期资产支付的现金

     投资支付的现金                    192,002,890.17                         671,189,815.05

     质押贷款净增加额

     取得子公司及其他营业单位支
付的现金净额

     支付其他与投资活动有关的现


投资活动现金流出小计                   297,923,987.07                         810,323,599.75


                                                                                          22
                                          深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文


投资活动产生的现金流量净额                       -39,000,310.26                      -339,025,043.35

三、筹资活动产生的现金流量:

     吸收投资收到的现金

     其中:子公司吸收少数股东投资
收到的现金

     取得借款收到的现金                          537,897,041.39                      781,622,713.53

     发行债券收到的现金

     收到其他与筹资活动有关的现
                                                   2,160,386.65                             2,145.82


筹资活动现金流入小计                             540,057,428.04                      781,624,859.35

     偿还债务支付的现金                          405,428,867.07                      787,179,736.50

     分配股利、利润或偿付利息支付
                                                  30,660,919.80                       16,955,743.70
的现金

     其中:子公司支付给少数股东的
股利、利润

     支付其他与筹资活动有关的现
                                                   4,174,999.43                         8,793,777.31


筹资活动现金流出小计                             440,264,786.30                      812,929,257.51

筹资活动产生的现金流量净额                        99,792,641.74                       -31,304,398.16

四、汇率变动对现金及现金等价物的
                                                 -10,491,712.00                        -2,150,661.47
影响

五、现金及现金等价物净增加额                       2,074,646.70                      -435,530,911.56

     加:期初现金及现金等价物余额           3,489,713,955.16                      4,545,240,436.15

六、期末现金及现金等价物余额                3,491,788,601.86                      4,109,709,524.59


6、母公司现金流量表

                                                                                            单位:元

              项目                  本期发生额                          上期发生额

一、经营活动产生的现金流量:

     销售商品、提供劳务收到的现金                380,734,060.71                      117,315,562.43

     收到的税费返还                               26,457,401.65                         5,251,806.82

     收到其他与经营活动有关的现
                                                  14,112,103.97                       22,148,526.44


经营活动现金流入小计                             421,303,566.33                      144,715,895.69

     购买商品、接受劳务支付的现金                346,663,132.61                      225,245,709.11

     支付给职工以及为职工支付的                   57,033,745.96                       50,556,844.50


                                                                                                  23
                                    深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文


现金

     支付的各项税费                     15,435,827.38                          25,661,581.32

     支付其他与经营活动有关的现
                                        13,465,326.34                          15,667,361.72


经营活动现金流出小计                   432,598,032.29                         317,131,496.65

经营活动产生的现金流量净额              -11,294,465.96                       -172,415,600.96

二、投资活动产生的现金流量:

     收回投资收到的现金                200,528,825.81                         439,000,000.00

     取得投资收益收到的现金              3,982,568.87                           3,352,418.77

     处置固定资产、无形资产和其他
                                                                                     830.00
长期资产收回的现金净额

     处置子公司及其他营业单位收
到的现金净额

     收到其他与投资活动有关的现


投资活动现金流入小计                   204,511,394.68                         442,353,248.77

     购建固定资产、无形资产和其他
                                        82,068,668.51                          51,823,724.36
长期资产支付的现金

     投资支付的现金                    133,332,163.89                         550,239,456.82

     取得子公司及其他营业单位支
付的现金净额

     支付其他与投资活动有关的现


投资活动现金流出小计                   215,400,832.40                         602,063,181.18

投资活动产生的现金流量净额              -10,889,437.72                       -159,709,932.41

三、筹资活动产生的现金流量:

     吸收投资收到的现金

     取得借款收到的现金                119,874,386.54                         340,000,000.00

     发行债券收到的现金

     收到其他与筹资活动有关的现


筹资活动现金流入小计                   119,874,386.54                         340,000,000.00

     偿还债务支付的现金                186,000,000.00                         340,399,513.50

     分配股利、利润或偿付利息支付
                                        16,550,276.38                           1,900,830.51
的现金

     支付其他与筹资活动有关的现
                                         4,426,288.81                           7,579,388.55



                                                                                          24
                                    深圳市海普瑞药业集团股份有限公司 2018 年第一季度报告全文


筹资活动现金流出小计                   206,976,565.19                         349,879,732.56

筹资活动产生的现金流量净额              -87,102,178.65                         -9,879,732.56

四、汇率变动对现金及现金等价物的
                                         -1,829,055.41                            146,311.27
影响

五、现金及现金等价物净增加额           -111,115,137.74                       -341,858,954.66

     加:期初现金及现金等价物余额     3,227,938,630.55                      4,114,026,165.90

六、期末现金及现金等价物余额          3,116,823,492.81                      3,772,167,211.24


二、审计报告

第一季度报告是否经过审计
□ 是 √ 否

       公司第一季度报告未经审计。




                                                         深圳市海普瑞药业集团股份有限公司

                                                                     法定代表人:李锂

                                                                         2018年4月26日




                                                                                          25
数据加载中...
prevnext
手机查看股票